| Accession | PRJCA003387 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Title | Research and development of personalized therapeutic targets and new technology for obesity and type 2 diabetes | ||||||||
| Relevance | Medical | ||||||||
| Data types |
Whole genome sequencing
Variation Genome sequencing omics |
||||||||
| Organisms | Homo sapiens | ||||||||
| Description | Type 2 diabetes is a complex disease caused by a combination of genetic and environmental factors, with considerable inter-individual heterogeneity in susceptibility, related phenotypes, and response of treatment. Although there are many studies on the association of omics data and diabetes, the pathophysiological basis of different phenotypes of diabetes is still unclear, and there is also a lack of clinical biomarkers and personalized drug targets. Therefore, this project aims to discover clinical markers of diabetes based on multi-omics data, combined with the research of various animal models and the application of new computing technologies, and provide theoretical basis for individualized drug development. We conducted studies including discovery of biomarkers by multi-omics, new molecular network pathways and regulation technology and the target of clinical personalized drugs, based on multiple cohort studies and intervention studies, a variety of human tissues and organs and animal model research platform. We did the analysis with multi-omics data by kinds of machine learning methods and we found some biomarkers of diabetes including lipids, proteins and miRNAs and revealed some of mechanisms. By establishing a new algorithm with "edge" instead of "node" and integrating multi-omics data, we established and validated the classification and prediction model of diabetes. Besides, the relevant mechanisms of different miRNAs with different type of diabetes were explored in cell and animal models. In addition, the intervention experiment of berberine combined with probiotics revealed a potential target and the mechanism of action of berberine for hypoglycemia from the perspective of intestinal bacteria-bile acid axis. In summary, our results has extremely important scientific significance and social value by providing a theoretical basis for more effective diabetes prevention and treatment, the discovery of personalized drug targets and the development of new drugs. | ||||||||
| Sample scope | Multiisolate | ||||||||
| Release date | 2022-09-04 | ||||||||
| Grants |
|
||||||||
| Submitter | Xu Lin (xlin@sibs.ac.cn) | ||||||||
| Organization | Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences | ||||||||
| Submission date | 2020-08-12 |
| Resource name | Description |
|---|---|
| BioSample (1392) show | - |